A method of administering to a patient in need thereof or contacting with a biological sample, a compound related to Formula I-e ##STR00001##
or pharmaceutically acceptable compositions thereof, is useful to inhibit activity of TLR7/8 or a mutant thereof and/or to treat a TLR7/8-mediated disorder.

Provided are an organic compound and an application thereof. The organic compound has a structure represented by Formula I. Through the design of a molecular structure, the organic compound has suitable HOMO and LUMO energy levels, high singlet energy level, good optoelectronic performance, a high glass transition temperature and good thermal stability, easily forms a good amorphous film, and is suitable for the machining and use of an OLED device. The organic compound, when used in the OLED device, may be used as a light-emitting layer material, an electron transport material or a hole blocking material and especially suitable for use as a host material of the light-emitting layer and can effectively improve the luminescence efficiency of the device, improve the device stability, extend lifetime, and reduce an operating voltage and energy consumption so that the OLED device has significantly improved performance such as luminescence efficiency, lifetime and energy consumption.

Provided are an organic compound and an application thereof. The organic compound has a structure represented by Formula I. Through the design of a molecular structure, the organic compound has suitable HOMO and LUMO energy levels, high singlet energy level, good optoelectronic performance, a high glass transition temperature and good thermal stability, easily forms a good amorphous film, and is suitable for the machining and use of an OLED device. The organic compound, when used in the OLED device, may be used as a light-emitting layer material, an electron transport material or a hole blocking material and especially suitable for use as a host material of the light-emitting layer and can effectively improve the luminescence efficiency of the device, improve the device stability, extend lifetime, and reduce an operating voltage and energy consumption so that the OLED device has significantly improved performance such as luminescence efficiency, lifetime and energy consumption.

A preparation method of Cu—Pd—CeO.sub.2/γ-Al.sub.2O.sub.3@NP catalyst and a synthesis method of benzopyrazine compounds. The preparation method of the Cu—Pd—CeO.sub.2/γ-Al.sub.2O.sub.3@NP catalyst comprises the following steps: (1) preparing a CeO.sub.2/γ-Al.sub.2O.sub.3 carrier; (2) preparing a CeO.sub.2/γ-Al.sub.2O.sub.3@NP carrier; (3) preparing the Cu—Pd—CeO.sub.2/γ-Al.sub.2O.sub.3@NP catalyst by impregnation method. A one-pot method for synthesizing benzopyrazine compounds of formula (III) includes using an o-nitroaniline compound of formula (I) and an aliphatic diol compound of formula (II) as raw materials, carrying out the one-pot synthesis of the benzopyrazine compound of formula (III) under solvent-free condition and under the combined action of the Cu—Pd—CeO.sub.2/γ-Al.sub.2O.sub.3@NP catalyst prepared by the method and an alkali. The Cu—Pd—CeO.sub.2/γ-Al.sub.2O.sub.3@NP catalyst increases the number of basic sites by doping N and P, and meanwhile loads CeO.sub.2 to assist in the extraction of protons, thereby improving the dehydrogenation activity and product selectivity.

A preparation method of Cu—Pd—CeO.sub.2/γ-Al.sub.2O.sub.3@NP catalyst and a synthesis method of benzopyrazine compounds. The preparation method of the Cu—Pd—CeO.sub.2/γ-Al.sub.2O.sub.3@NP catalyst comprises the following steps: (1) preparing a CeO.sub.2/γ-Al.sub.2O.sub.3 carrier; (2) preparing a CeO.sub.2/γ-Al.sub.2O.sub.3@NP carrier; (3) preparing the Cu—Pd—CeO.sub.2/γ-Al.sub.2O.sub.3@NP catalyst by impregnation method. A one-pot method for synthesizing benzopyrazine compounds of formula (III) includes using an o-nitroaniline compound of formula (I) and an aliphatic diol compound of formula (II) as raw materials, carrying out the one-pot synthesis of the benzopyrazine compound of formula (III) under solvent-free condition and under the combined action of the Cu—Pd—CeO.sub.2/γ-Al.sub.2O.sub.3@NP catalyst prepared by the method and an alkali. The Cu—Pd—CeO.sub.2/γ-Al.sub.2O.sub.3@NP catalyst increases the number of basic sites by doping N and P, and meanwhile loads CeO.sub.2 to assist in the extraction of protons, thereby improving the dehydrogenation activity and product selectivity.

The present disclosure provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.

Provided herein are anti-fibrotic compounds, in particular those of Formula (I), that inhibit the TGF-beta signaling pathway. Also provided are pharmaceutical compositions comprising the anti-fibrotic compounds, and methods of treating diseases or conditions associated with fibrosis, inflammation, and benign or malignant neoplastic diseases in a subject by administering a compound or composition described herein.

Provided herein are anti-fibrotic compounds, in particular those of Formula (I), that inhibit the TGF-beta signaling pathway. Also provided are pharmaceutical compositions comprising the anti-fibrotic compounds, and methods of treating diseases or conditions associated with fibrosis, inflammation, and benign or malignant neoplastic diseases in a subject by administering a compound or composition described herein.

The present disclosure relates to an organic electroluminescent compound and an organic electroluminescent device comprising the same. By using the organic electroluminescent compound of the present disclosure, an organic electroluminescent device having high luminous efficiency and/or long lifespan properties can be provided compared to conventional organic electroluminescent devices.

The present disclosure relates to a plurality of host materials comprising a first host material having a compound represented by formula 1, and a second host material having a compound represented by formula 2, and an organic electroluminescent device comprising the same. By comprising a specific combination of compounds of the present disclosure as host materials, it is possible to provide an organic electroluminescent device having long lifetime properties while having an equivalent or improved level of power efficiency compared to conventional organic electroluminescent devices.